NASDAQ:HSGX - Histogenics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.56 +0.02 (+3.70 %)
(As of 09/19/2018 04:00 PM ET)
Previous Close$0.54
Today's Range$0.53 - $0.58
52-Week Range$0.51 - $3.35
Volume645,400 shs
Average Volume295,103 shs
Market Capitalization$15.49 million
P/E Ratio-0.58
Dividend YieldN/A
Histogenics logoHistogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.

Receive HSGX News and Ratings via Email

Sign-up to receive the latest news and ratings for HSGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical appliances & supplies


Debt-to-Equity RatioN/A
Current Ratio0.83
Quick Ratio0.83


Trailing P/E Ratio-0.58
Forward P/E Ratio-0.79
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.46) per share
Price / Book-1.22


EPS (Most Recent Fiscal Year)($0.98)
Net Income$-26,410,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-160.97%


Outstanding Shares29,240,000
Market Cap$15.49 million

Histogenics (NASDAQ:HSGX) Frequently Asked Questions

What is Histogenics' stock symbol?

Histogenics trades on the NASDAQ under the ticker symbol "HSGX."

How were Histogenics' earnings last quarter?

Histogenics Corp (NASDAQ:HSGX) announced its quarterly earnings data on Thursday, August, 9th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.23) by $0.10. View Histogenics' Earnings History.

When is Histogenics' next earnings date?

Histogenics is scheduled to release their next quarterly earnings announcement on Thursday, November, 8th 2018. View Earnings Estimates for Histogenics.

What price target have analysts set for HSGX?

5 Wall Street analysts have issued 1-year target prices for Histogenics' stock. Their forecasts range from $2.00 to $5.00. On average, they anticipate Histogenics' stock price to reach $3.6250 in the next twelve months. This suggests a possible upside of 547.3% from the stock's current price. View Analyst Price Targets for Histogenics.

What is the consensus analysts' recommendation for Histogenics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Histogenics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Histogenics.

What are Wall Street analysts saying about Histogenics stock?

Here are some recent quotes from research analysts about Histogenics stock:
  • 1. HC Wainwright analysts commented, "We maintain our Buy rating of HSGX and lower our 12-month price target to $2.00 per share, down from $3.50. We derive our price target based on a risk-adjusted net present value analysis of projected NeoCart revenues until 2027 assuming a 12% discount rate and a 3% terminal value. We derive an rNPV of $97M for NeoCart and add $9M in cash and cash equivalents to arrive at a 12-month price target of $1.99 per diluted share, which we round to $2.00. (1) clinical; (2) commercial; (3) partnership; (4) financial; and (5) legal and intellectual property." (9/5/2018)
  • 2. According to Zacks Investment Research, "Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. " (8/16/2018)

Are investors shorting Histogenics?

Histogenics saw a increase in short interest in the month of August. As of August 15th, there was short interest totalling 969,528 shares, an increase of 81.5% from the July 31st total of 534,173 shares. Based on an average daily volume of 277,489 shares, the days-to-cover ratio is currently 3.5 days. Currently, 5.7% of the shares of the company are sold short. View Histogenics' Current Options Chain.

Who are some of Histogenics' key competitors?

Who are Histogenics' key executives?

Histogenics' management team includes the folowing people:
  • Mr. Adam D. Gridley, Pres, CEO & Director (Age 46)
  • Mr. Jonathan I. Lieber, Chief Financial Officer (Age 48)
  • Mr. Stephen R. Kennedy, Exec. VP & COO (Age 61)
  • Dr. Donald D. Haut, Chief Bus. Officer (Age 52)
  • Dr. E. Lynne Kelley M.D., FACS, Chief Medical Officer (Age 55)

When did Histogenics IPO?

(HSGX) raised $60 million in an initial public offering (IPO) on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

Has Histogenics been receiving favorable news coverage?

Headlines about HSGX stock have trended somewhat positive this week, Accern reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Histogenics earned a news and rumor sentiment score of 0.18 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for Histogenics.

Who are Histogenics' major shareholders?

Histogenics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.34%), DRW Securities LLC (0.34%) and BlackRock Inc. (0.19%). Company insiders that own Histogenics stock include Adam Gridley, David N Gill, Jonathan I Lieber and Split Rock Partners Ii, Lp. View Institutional Ownership Trends for Histogenics.

Which institutional investors are buying Histogenics stock?

HSGX stock was acquired by a variety of institutional investors in the last quarter, including DRW Securities LLC, BlackRock Inc. and Renaissance Technologies LLC. Company insiders that have bought Histogenics stock in the last two years include Adam Gridley, David N Gill, Jonathan I Lieber and Split Rock Partners Ii, Lp. View Insider Buying and Selling for Histogenics.

How do I buy shares of Histogenics?

Shares of HSGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Histogenics' stock price today?

One share of HSGX stock can currently be purchased for approximately $0.56.

How big of a company is Histogenics?

Histogenics has a market capitalization of $15.49 million. The biotechnology company earns $-26,410,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Histogenics employs 45 workers across the globe.

How can I contact Histogenics?

Histogenics' mailing address is 830 WINTER STREET 3RD FLOOR, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-547-7900 or via email at [email protected]

MarketBeat Community Rating for Histogenics (NASDAQ HSGX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  234 (Vote Outperform)
Underperform Votes:  174 (Vote Underperform)
Total Votes:  408
MarketBeat's community ratings are surveys of what our community members think about Histogenics and other stocks. Vote "Outperform" if you believe HSGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/19/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel